Presentation on theme: "Department of Pediatric Surgery and Oncology Laboratory for Vascular Anomalies Medical University of Lodz Foam sclerotherapy in treatment of venous malformations."— Presentation transcript:
Department of Pediatric Surgery and Oncology Laboratory for Vascular Anomalies Medical University of Lodz Foam sclerotherapy in treatment of venous malformations in children. Tutor: Assoc. Prof. Przemysław Przewratil MD, PhD Michał Kowalczyk
International Society for the Study of Vascular Anomalies ISSVA Classification V A S C U L A R A N O M A L I E S TUMORSMALFORMATIONS Infantile haemangioma Low-flowFast-Flow Venous malformation (VM) Arterial malformation (AM) Capillary malformation (CM) Arteriovenous fistula (AVF) Lymphatic malformation (LM) Arteriovenous malformation (AVM)
Venous malformation lesion composed of abnormal collections of veins mostly localized in the skin can affect any other tissue or organ cutaneous and subcutaneous tissue muscles joints intestines most frequent low-flow vascular malformations may cause cosmetic or functional defects as well as physical disability http://www.hopkinsmedicine.org/sebin/w/u/malformation_2.gif
Dubois and Puig Classification Orthop Clin N Am 2006, 37, 435-474
A percutaneous injection of a sclerosing substance directly into a lesion. Prior to injection the sclerosing agent is mixed with air to make a foam. Sclerosant agent causes obliteration http://t1.gstatic.com/images?q=tbn:ANd9GcStEyuOGqnD3vcw qhnLdVN_pYvKmkvw9erHjOG9omc-1rQv_xV9 of the vessel, what effects in sealing off the blood flow. It may be administered as an only procedure or in combination with surgical resection. Multiple sessions are often required to achieve visual improvement or permanent results. Foam sclerotherapy
Analysis of the results of the treatment of venous malformations using foam sclerotherapy. Aim of a study
Retrospective analysis 34 patients treated between June 2006 and December 2011 20 female (59%), 14 male (41%) Age range: 1-15 (average 7 years) Foam sclerotherapy Polidocanol (Aethoxysclerol) 1% / 3% | 1 – 6ml Assessment by US, MRI Phlebography Performed prior to the sclerotherapy in 19 patients (56%) Surgical resection Preceded by sclerotherapy - 6 patients (18%) Duration of hospital stay – ranged from 1 to 5 days (average 2,5) Material & Methods
Results Temporary side effects were observed in 2 (6%) patients. Vasculitis – 1 case Skin necrosis – 1 case Initial phlebography increased significantly the effectiveness and safety of each sclerotherapy. In 6 patients (18%) sclerotherapy preceded the surgical resection improving their performance. Adopted method was rated by parents and patients as effective and hardly invasive.
Conclusions 1.VMs treatment is based on a proper diagnosis according to ISSVA classification, differentiating them from infantile hemangiomas. 1.Sclerotherapy with polidaconol used as foam is effective and safe managment of VMs.